These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Salve preparations according to old and new guiding rules]. Becher K Dtsch Apoth Ztg; 1965 Aug; 105(33):1104-8. PubMed ID: 5858152 [No Abstract] [Full Text] [Related]
29. [Manufacturing of ointments in the form of tablets]. Popović B; Topalov V; Popović R Vojnosanit Pregl; 1966 Oct; 23(10):587-9. PubMed ID: 5978653 [No Abstract] [Full Text] [Related]
30. [The Suppo-set STADA for the molding and packaging of suppositories]. Pharm Weekbl; 1972 Jul; 107(30):480-2. PubMed ID: 4639083 [No Abstract] [Full Text] [Related]
31. [Penetrometry and Velon's relation]. Delonca H; Dolique R; Bardet L Ann Pharm Fr; 1965; 23(9):551-60. PubMed ID: 5851854 [No Abstract] [Full Text] [Related]
32. [Assessment of the mechanical contamination of ointments in the process of their preparation]. Zhurko VV; Dobrotvorskiĭ AE Farmatsiia; 1977; 26(5):64-5. PubMed ID: 913634 [No Abstract] [Full Text] [Related]
33. [Importance of the container for cosmetic products]. Caló A; Sampaolo A Boll Chim Farm; 1972 Dec; 111(12):718-23. PubMed ID: 4656464 [No Abstract] [Full Text] [Related]
36. [Preparation of ointments on a 5 per cent methylcellulose solution in pharmacies]. Riaposova OI; Nazarov BV Farmatsiia; 1973; 22(3):14-7. PubMed ID: 4774731 [No Abstract] [Full Text] [Related]
37. Deterioration of substances used for patch testing. Trolle-Lassen C; Hjorth N Berufsdermatosen; 1966 Aug; 14(4):176-88. PubMed ID: 5994822 [No Abstract] [Full Text] [Related]
38. [On the particle size of drugs incorporated in eye ointments]. DODEN W; BOEKER W Klin Monbl Augenheilkd Augenarztl Fortbild; 1959; 135():305-47. PubMed ID: 13817140 [No Abstract] [Full Text] [Related]
39. Development and manufacture of ophthalmic products. Mullins JD Bull Parenter Drug Assoc; 1966; 20(2):48-55. PubMed ID: 5905228 [No Abstract] [Full Text] [Related]
40. [Risks in the delivery of drugs from the point of manufacture to the patient. I. Risks in manufacturing and compounding]. Samková M; Solich J Cesk Farm; 1981 Dec; 30(10):349-54. PubMed ID: 7332939 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]